You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RP2D

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Cancer Trial (BNT321 Dose Level 1, BNT321 Dose Level 2, mFOLFIRINOX)

Not yet recruiting
  • Pancreatic Cancer
  • BNT321 Dose Level 1
  • +3 more
  • (no location specified)
Sep 29, 2023

Leukemia, Myeloid, Acute Trial (GSK3745417)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • (no location specified)
Jun 15, 2022

Advanced Solid Tumor, Ovarian Cancer Trial in Richmond (Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg)

Recruiting
  • Advanced Solid Tumor
  • Ovarian Cancer
  • Neratinib 160 mg
  • +7 more
  • Richmond, Virginia
    Virginia Commonwealth University
May 6, 2022

Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma Trial (Lurbinectedin)

Not yet recruiting
  • Refractory Ewing Sarcoma
  • +2 more
  • (no location specified)
Feb 15, 2023

Solid Tumors Trial (ARTS-021, CDK 4/6 inhibitor, Fulvestrant 50 MG/ML Prefilled Syringe)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
May 17, 2023

Pancreas Cancer, Gastric Cancer, Solid Tumor Trial (1 mg/kg IV FL-301, 3 mg/kg IV FL-301, 10 mg/kg IV FL-301)

Withdrawn
  • Pancreas Cancer
  • +2 more
  • 1 mg/kg IV FL-301
  • +5 more
  • (no location specified)
Jan 31, 2022

Acute Myeloid Leukemia Trial in Baltimore (Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Dose Escalation -tagraxofusp-erzs
  • Dose Expansion at RP2D -tagraxofusp-erzs
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 27, 2023

Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with

Recruiting
  • Inhibition of Autophagy Synergizes Anti-tumor Effect
  • 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
  • RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023

Solid Tumor, Adult Trial in United States (IO-202, IO-202 + pembrolizumab combination therapy, RP2D of IO-202 + pembrolizumab

Not yet recruiting
  • Solid Tumor, Adult
  • IO-202
  • +2 more
  • Los Angeles, California
  • +3 more
Mar 25, 2022

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Jul 23, 2022

Solid Tumor, Adult Trial in United States (GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose)

Recruiting
  • Solid Tumor, Adult
  • GAd-209-FSP low dose
  • +5 more
  • Duarte, California
  • +12 more
Oct 2, 2022

Cancer Trial in Spain, United Kingdom (RP2, nivolumab)

Recruiting
  • Cancer
  • RP2
  • nivolumab
  • Barcelona, Spain
  • +5 more
Nov 11, 2022

Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma Trial in Australia (AMP945 ascending doses, AMP945 RP2D)

Recruiting
  • Pancreatic Cancer
  • +2 more
  • AMP945 ascending doses
  • AMP945 RP2D
  • St Leonards, New South Wales, Australia
  • +6 more
Dec 7, 2022

Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,

Not yet recruiting
  • Recurrent Bladder Carcinoma
  • +2 more
  • Pharmacokinetic Study
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023

NSCLC (NSCLC) Trial in Tampa (PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg)

Completed
  • Non-small Cell Lung Cancer (NSCLC)
  • PBF-509_80 mg
  • +8 more
  • Tampa, Florida
    H.Lee Moffitt Cancer center
Jan 3, 2022

Advanced Solid Tumor, Colorectal Cancer, Lung Cancer Trial in Randwick (KF-0210 tablets, 120 mg, KF-0210 tablets, 240 mg,

Recruiting
  • Advanced Solid Tumor
  • +5 more
  • KF-0210 tablets, 120 mg
  • +6 more
  • Randwick, New South Wales, Australia
    Scientia Clinical Research Limited
Aug 31, 2021

Advanced Solid Tumor, Endometrial Carcinoma, Hormone Receptor Positive Trial in Lyon, Nantes, Toulouse (NP137 DL and RP2D)

Completed
  • Advanced Solid Tumor
  • +2 more
  • NP137 DL and RP2D
  • Lyon, France
  • +2 more
Jul 22, 2022

Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer Trial in Aurora, Nashville, Houston

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +4 more
  • Aurora, Colorado
  • +2 more
Apr 18, 2022

Hepatocellular Carcinoma, Liver Cancer, Liver Tumor Trial in United States (ET140203 autologous T cell product)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • ET140203 autologous T cell product
  • Duarte, California
  • +3 more
Jul 1, 2022

Relapsed/Refractory Multiple Myeloma Trial in Australia, United States (ISB 1442 SC injection escalating doses, ISB 1442 SC

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 1442 SC injection escalating doses
  • ISB 1442 SC injection at RP2D
  • New York, New York
  • +5 more
Jun 17, 2022

Metastatic Breast Cancer Trial in Duarte (huMNC2-CAR44 CAR T cells, huMNC2-CAR44 CAR T cells @ RP2D)

Recruiting
  • Metastatic Breast Cancer
  • huMNC2-CAR44 CAR T cells
  • huMNC2-CAR44 CAR T cells @ RP2D
  • Duarte, California
    City of Hope Medical Center
Dec 22, 2021

Multiple Myeloma Trial (CM336_group 1, CM336_group 2a, CM336_group 2b)

Not yet recruiting
  • Multiple Myeloma
  • CM336_group 1
  • +14 more
  • (no location specified)
Mar 18, 2022

Advanced Solid Tumors Cancer Trial in Worldwide (ABBV-151, Budigalimab)

Recruiting
  • Advanced Solid Tumors Cancer
  • New Haven, Connecticut
  • +29 more
Dec 5, 2022

Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal

Recruiting
  • Cervical Esophagus Adenocarcinoma
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Retinitis Pigmentosa Trial in Paris (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))

Active, not recruiting
  • Retinitis Pigmentosa
  • Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)
  • Paris, France
    •Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-V
Jan 11, 2023